New personalized cancer vaccine in initial human clinical trial in advanced ovarian cancer patients found half of vaccinated patients showed signs of anti-tumor responses and lived longer. One patient, after 2 years of vaccinations, was disease-free for another 5 years without further treatment.

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania. The personalized vaccine is made from patients? own immune cells, which are exposed in the laboratory to the contents of the patients? tumor cells, and then injected into the patients to initiate a wider immune response.

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →